GlassScriptPhysician profile
Joan Parambi
NPI 1285839415
$2,473.73
in general payments reported to CMS, 2019-2025
31 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $40.89 · 2021: $58.59 · 2022: $448 · 2023: $559 · 2024: $157 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $484.66 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $340.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $182.96 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $174.29 | 2019-2025 | |
| Corcept Therapeutics | $161.79 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $157.53 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $77.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.79 | 2025 | Jardiance |
| Exact Sciences Corporation | $71.14 | 2024-2025 | Cologuard Collection Kit |
| Amphastar Pharmaceuticals, INC. | $66.75 | 2025 | |
| Beta Bionics, INC. | $62.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $61.42 | 2024-2025 | Tepezza, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $57.91 | 2022-2025 | |
| Insulet Corporation | $45.93 | 2022-2025 | Omnipod |
| Antares Pharma, INC. | $45.46 | 2019-2025 | Xyosted |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $43.62 | 2019 | |
| Abbvie INC. | $43.10 | 2019 | |
| Neurocrine Biosciences, INC. | $32.30 | 2025 | |
| Madrigal Pharmaceuticals | $32.29 | 2025 | Rezdiffra |
| Mannkind Corporation | $32.21 | 2025 | |
| Medtronic, INC. | $31.91 | 2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $30.48 | 2025 | Gardasil 9, Capvaxive |
| Cequr Corporation | $22.54 | 2023 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $20.33 | 2022 | |
| Eusa Pharma (US) LLC | $20.33 | 2022 | |
| Amneal Pharmaceuticals LLC | $20.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.98 | 2022 | |
| Ascensia Diabetes Care US INC. | $18.16 | 2022 | |
| Lifescan, INC. | $15.84 | 2021 | |
| Tandem Diabetes Care, INC. | $15.18 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Parambi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.